JESSICA ONUFRAK: Open Payments
NPI 1326474248 · MARYSVILLE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$629 in 34 payments from 17 companies in 2025. Trend: 2023 $930 · 2024 $885 · 2025 $629
Food & beverage: $629
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 5 | $88 |
| Novo Nordisk Inc | 4 | $74 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Astellas Pharma US Inc | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| ABBVIE INC. | 2 | $39 |
| Lilly USA, LLC | 2 | $33 |
| Biogen, Inc. | 1 | $30 |
Products named: Wegovy, TRELEGY ELLIPTA, Veozah, OTEZLA, REXULTI, XIFAXAN, EVENITY, VRAYLAR.
Industry payments across MI — which companies pay providers there.
